Interleukin-6

Association between the -174 G/C polymorphism of the interleukin-6 gene and myocardial infarction risk: a meta-analysis

J. Zhou, Feng, J., Li, X., Zhou, J., Feng, J., and Li, X., Association between the -174 G/C polymorphism of the interleukin-6 gene and myocardial infarction risk: a meta-analysis, vol. 15, p. -, 2016.

Numerous studies have evaluated the association between the -174 G/C polymorphism in the interleukin-6 gene (IL6) and myocardial infarction (MI) risk. However, the results from the published studies are inconclusive. The aim of this meta-analysis was to determine whether the IL6 -174 G/C polymorphism is associated with MI risk. A meta-analysis based on nine case-control studies was performed to address this issue.

Interleukin-6 -572G/C polymorphism and prostate cancer susceptibility

W. J. Huang, Wu, L. J., Min, Z. C., Xu, L. T., Guo, C. M., Chen, Z. P., Lou, X. J., Xu, B., Lv, B. D., Huang, W. J., Wu, L. J., Min, Z. C., Xu, L. T., Guo, C. M., Chen, Z. P., Lou, X. J., Xu, B., and Lv, B. D., Interleukin-6 -572G/C polymorphism and prostate cancer susceptibility, vol. 15, p. -, 2016.

Strong evidence suggests that cancer-associated inflammation promotes tumor growth and progression, and interleukin-6 (IL6) is an important modulator of inflammation. However, the roles of IL6 and mutations of its corresponding gene in prostate cancer have not been clearly documented. We retrieved data from the Oncomine database concerning IL6 expression in prostate cancer and its role in prostate-specific antigen (PSA) recurrence.

Subscribe to Interleukin-6